Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina, Inc. (NASDAQ: ILMN) is at the forefront of genomic technology, providing innovative tools and services to analyze genetic material. With a primary focus on DNA sequencing and array-based technologies, Illumina serves a diverse range of markets including life sciences, oncology, reproductive health, and agriculture. Over 90% of its revenue stems from sequencing instruments, consumables, and services, with the remainder coming from microarrays used in genetic screening for consumer and agricultural applications. Illumina's technology enables high-throughput whole genome sequencing, which is essential for large-scale genomic studies, as well as lower throughput tools for specific applications such as viral and cancer tumor screening.
Recent advancements at Illumina include the upcoming release of their first quarter 2024 financial results, showcasing significant improvements in both gross and non-GAAP operating margins. The company's innovative solutions continue to drive sequencing activity globally, despite challenging economic conditions. Illumina's NovaSeq X Sequencing System exemplifies their cutting-edge research and development efforts, demonstrating the company's commitment to delivering superior technology for genomic analysis.
In the oncology domain, Illumina's Whole-Genome Sequencing (WGS) and Comprehensive Genomic Profiling (CGP) are setting new standards for cancer diagnostics and treatment. By collaborating with leading institutions and pharmaceutical companies, Illumina is enhancing the scientific understanding of cancer biology and developing advanced assays for Molecular Residual Disease (MRD) detection. These efforts are crucial in precision oncology, enabling early detection and personalized treatment strategies.
Illumina is also committed to expanding access to genomic testing. Through initiatives like The Future Is Bright and partnerships with educational institutions, the company is fostering the next generation of scientists. Their volunteer programs and educational outreach aim to increase genomic literacy and inspire students to pursue careers in STEM fields.
Furthermore, Illumina's ongoing collaboration with GRAIL, Inc., a wholly-owned subsidiary focused on early cancer detection, highlights the company's dedication to transformative healthcare solutions. Despite regulatory challenges, Illumina remains steadfast in its mission to unlock the power of the genome and improve human health.
Stay updated with Illumina's latest developments and financial performance by visiting their website and connecting on social media platforms like X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Illumina reported record fourth-quarter revenue of $953 million, a 20% increase from Q3 2020 and slightly higher than 2019. GAAP net income for the quarter was $257 million ($1.75/share), up from $239 million ($1.61/share) year-over-year. However, non-GAAP net income decreased to $179 million ($1.22/share) from $252 million ($1.70/share). Full-year revenue dropped 9% to $3,239 million, and GAAP net income fell to $656 million from $1,002 million in 2019. The company projects 2021 revenue growth of 17% to 20% and earnings per share of $4.76 to $5.01.
Illumina (NASDAQ:ILMN) announced its executives will speak at two upcoming investor conferences. The first event is the SVB Leerink Annual Global Healthcare Conference on February 25, 2021, at 12:00 PM PT. The second is the Cowen Annual Health Care Conference on March 2, 2021, at 9:50 AM PT. Investors can join the webcasts via the company's website, where replays will be available for 30 days post-event. Illumina is a leader in DNA sequencing technologies, serving various markets including oncology and agriculture.
Illumina (NASDAQ: ILMN) has announced the selection of nine new genomics startups for its second global funding cycle of Illumina Accelerator in the U.S. and UK. The company secured over £20 million in UK capital commitments from investors, including a £10 million commitment from LifeArc. These funds will match investments for Accelerator graduates, enhancing support for genomics innovations. Illumina Accelerator offers startups seed investments, access to technologies, and operational support. Applications for the next funding cycle are open until March 1, 2021.
Illumina (NASDAQ:ILMN) has partnered with the Belgian Society of Medical Oncology to launch the BALLETT study, aimed at evaluating comprehensive genomic profiling (CGP) in 864 patients with advanced metastatic cancer. Beginning next month, the study will involve twelve sites offering CGP using Illumina's TruSight™ Oncology 500 and sequencing platforms. This initiative seeks to enhance patient treatment options through targeted therapies, leveraging genomic data to improve clinical outcomes and establish a national genomic tumor database in Belgium.
Illumina (NASDAQ: ILMN) has partnered with Sequoia Capital China to launch the Sequoia Capital China Intelligent Healthcare Genomics Incubator, aimed at fostering genomics startups in China. This incubator will provide startups with resources like investment guidance, access to sequencing systems, and operational lab space in Shanghai. The inaugural funding cycle begins in Fall 2021, with applications open until June 1, 2021. Illumina's leadership in DNA sequencing and its successful previous incubators will support this initiative to enhance genomic innovations in a vibrant startup ecosystem.
Illumina, Inc. (NASDAQ:ILMN) is set to announce its fourth quarter and full year 2020 results on February 11, 2021, after market close. A conference call will follow at 2:00 PM PT (5:00 PM ET), hosted by CEO Francis deSouza and CFO Sam Samad, to discuss financial results and operational updates. Participants can join via the company's investor section or by dialing in. A replay of the call will be available on Illumina's website for 30 days.
Illumina (NASDAQ: ILMN) announced a favorable judgment from the High Court of Justice in a patent infringement case against BGI Companies, including MGI Tech. The Court affirmed the validity of four out of five asserted patents, confirming that BGI’s StandardMPS and CoolMPS systems infringe Illumina’s proprietary technologies. A preliminary injunction was issued against BGI in the UK, and Illumina plans to seek a permanent injunction to prevent BGI from selling the infringing products. Similar injunctions were previously issued in other countries against BGI.
Illumina, Inc. (NASDAQ: ILMN) has launched Illumina Connected Analytics (ICA), a cloud-based bioinformatics solution designed to facilitate management and analysis of multi-omic data. The platform aims to help researchers like those at the Montreal Neurological Institute and the Munich Leukemia Laboratory handle larger data volumes efficiently. With features emphasizing security, scalability, and cost-effectiveness, ICA enhances users' ability to process genomic data generated from over 17,000 sequencing systems. ICA will be available starting January 28, 2021.
Illumina (NASDAQ: ILMN) has unveiled new oncology partnerships, reaffirming its commitment to precision oncology tools during the 39th Annual J.P. Morgan Healthcare Conference. The company introduced TruSight Oncology 500 (TSO 500), a comprehensive pan-cancer assay identifying 523 biomarkers using DNA and RNA from tumors. Illumina is expanding its partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to develop companion diagnostics and enhance treatment selection. A new IVD test based on TSO 500 is under regulatory review, with a launch expected in the U.S. and Europe this year.
Illumina (Nasdaq: ILMN) has partnered with Helix to enhance U.S. surveillance of SARS-CoV-2 variants, with support from the CDC. Their collaboration aims to identify and monitor emerging strains, having already detected B.1.1.7 in multiple states. This initiative will expand genomic surveillance efforts, allowing for timely responses to changes in the virus's pathogenicity and treatment efficacy. Both companies emphasize the importance of genomic data in adapting public health strategies to combat COVID-19 variants.
FAQ
What is the current stock price of Illumina (ILMN)?
What is the market cap of Illumina (ILMN)?
What does Illumina, Inc. specialize in?
What are Illumina's main revenue sources?
How is Illumina contributing to cancer research?
What are some recent achievements of Illumina?
What is the role of GRAIL in Illumina's operations?
How is Illumina expanding genomic literacy?
Where can one find Illumina's latest news and updates?
What types of genomic analysis does Illumina technology support?
What educational programs does Illumina offer?
How is Illumina addressing the global cancer burden?
